ReviewInternational journal of molecular sciences2022
Current Molecular Combination Therapies Used for the Treatment of Breast Cancer.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022.Frontiers in oncology · 2024Pooled it
- Hereditary breast cancer: emerging roles of non-coding RNAs.Hereditas · 2026Review
- Integrative pipeline to profile and target endocrine therapy-insensitive cell populations in ER+ breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities.Biomedicines · 2026Review
- Computational Identification of New Dual PAK4 and NAMPT Inhibitors.International journal of molecular sciences · 2026Article
- Pyridopyrimidines and Pyridopyrimidinones as Kinase-Targeted Anticancer Agents: Medicinal Chemistry and Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
- Tanshinone IIA in breast cancer: Molecular mechanisms, structural optimization and translational challenges (Review).Oncology reports · 2026Review
- A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind.Molecular systems biology · 2026Article
- CRISPR/Cas9-mediated knockout of TopBP1 shifts the Bax/Bcl-2 balance toward apoptosis in MCF7 breast cancer cells.Molecular biology reports · 2026Article
- Integrating multi-omics and clinical management in breast cancer: a comprehensive review.Discover oncology · 2026Review
- A multi-targeted therapeutic strategy for triple-negative breast cancer: the tumor-targeting peptide p28 enhances chemotherapy, induces apoptosis, crosses the blood-brain barrier, and suppresses metastasis.Apoptosis : an international journal on programmed cell death · 2026Article
- Advances in targeting vasculogenic mimicry in malignant tumors using monomeric compounds from Traditional Chinese Medicine (Review).Oncology letters · 2026Review
- Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.Cancers · 2026Review
- The WISP1/Src/MIF Axis Promotes the Malignant Phenotype of Non-Invasive MCF7 Breast Cancer Cells.Cells · 2026Article
- VEGF-Leptin Crosstalk in Breast and Ovarian Cancer: Drivers of Angiogenesis and Progression.Cancer management and research · 2026Review
- EI24 suppresses TNBC tumorigenesis by regulating AKT signaling.Frontiers in oncology · 2026Article
- The efficacy of oligonucleotide-based gene therapeutics in gene silencing.Theranostics · 2026Review
- Computational decoding of cell-cycle phase effects on cancer hallmarks across breast cancer subtypes.Breast cancer research : BCR · 2025Article
- Dual-site spatiotemporal and simultaneous inhibition on PIN1 via arsenic-retinoic albumin nanoparticles enables synergistic oncotherapy.Journal of nanobiotechnology · 2025Article
- PI3 K/AKT/mTOR pathway and its role in breast cancer stem cells.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Breast cancer is the second leading cause of death for women worldwide. While monotherapy (single agent) treatments have been used for many years, they are not always effective, and many patients relapse after initial treatment. Moreover, in some patients the response to therapy becomes weaker, or resistance to monotherapy develops over time. This is especially problematic for metastatic breast cancer or triple-negative breast cancer. Recently, combination therapies (in which two or more drugs are used to target two or more pathways) have emerged as promising new treatment options. Combination therapies are often more effective than monotherapies and demonstrate lower levels of toxicity during long-term treatment. In this review, we provide a comprehensive overview of current combination therapies, including molecular-targeted therapy, hormone therapy, immunotherapy, and chemotherapy. We also describe the molecular basis of breast cancer and the various treatment options for different breast cancer subtypes. While combination therapies are promising, we also discuss some of the challenges. Despite these challenges, the use of innovative combination therapy holds great promise compared with traditional monotherapies. In addition, the use of multidisciplinary technologies (such as nanotechnology and computer technology) has the potential to optimize combination therapies even further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.